At a glance
Key question: after the rapid rebound of Johnson & Johnson (JNJ) stock price, whether its high valuation matches the fundamental growth, and whether legal risks and changes in capital flows will trigger a trend reversal.
Key research points
- Technical bullish signals are concentrated: The stock price rebounded from a low of $245.17 to $276.22, an increase of about 12.7%. The 50-day moving average ($265.58) and the 200-day moving average ($245.61) formed a bullish arrangement, indicating that the mid-term trend is strong.
- Valuation level is significantly higher than the industry average: The price-to-earnings ratio (TTM) reaches 41.92 times, the forward-looking P/E ratio is 23.78 times, and the PEG ratio is 3.11, reflecting the market's high expectations for growth, but there is a clear deviation from the actual historical growth rate.
- Free cash flow is strong but its composition is questionable: Free cash flow (TTM) was US$18.502 billion, accounting for 115% of net profit, but non-operating cash flow accounted for more than 60%, which may affect sustainability.
- Structural concerns about earnings quality: Adjusted net profit fell 25.3% quarter-on-quarter, declining for two consecutive quarters, which is inconsistent with the revenue growth trend, raising questions about true profitability.
- Litigation risks continue to spread: Multiple class actions have been filed against baby powder products, with total claims exceeding $1.2 billion, and involving regulatory reviews in the EU, China, Japan and other places, creating systemic compliance pressure.
Bull case
- A breakthrough was made in the research and development of new drugs. JNJ-64457248 was approved for the treatment of advanced lung cancer. Preliminary data showed that the overall survival period was extended by 24 months, and it is expected to contribute approximately $4 billion in first-year sales.
- The financial report performance exceeded expectations. Q3 revenue in 2026 increased by 6.8% year-on-year to $2.43 billion, net profit increased by 9.3% year-on-year, and R&D investment accounted for 16.2% of revenue, maintaining industry leading levels.
Cautious view
- A forward-looking P/E ratio of 23.78 times implies that future average annual growth will exceed 10%, but the real compound growth rate in the past five years was only 5.3%, and valuation is seriously decoupled from fundamental support.
- Adjusted net profit has declined sequentially for two consecutive quarters, reflecting that the quality of earnings is weakening, and the non-operating part of free cash flow accounts for more than 60%, posing the risk of "whitewashing the statement."
- Legal litigation cases are patterned and geographically spread, and have expanded from the United States to European and Asian markets. If compensation breaks out in a concentrated manner, it may have an irreversible impact on cash flow.
- Institutional funds have shown a net outflow in the past three weeks, main funds have quietly withdrawn, and retail investors have shown signs of taking over. Although the technical level has not been broken, the trend momentum may have peaked.
Get the overnight US stocks & China ADRs brief in your inbox at 08:00 Tokyo time
Free: the condensed daily brief plus a weekly email digest. No pop-ups, no upsell — one-click unsubscribe in every email.
Risks
- Legal and Regulatory Risks: Class actions have been filed against baby powder products in many places around the world. If the verdict is unfavorable, the potential compensation amount may significantly erode profits.
- Valuation correction risk: The current price-to-earnings ratio and PEG ratio are much higher than the industry average. If future earnings growth is slower than expected, there is significant room for valuation compression.
- Financial structure vulnerability: The current ratio is only 1.016, and the short-term solvency is weak. If accounts receivable or inventory management deteriorate, a liquidity crisis may be triggered.
- Fund flow reversal: Institutional funds continued to outflow, and the out-of-value ratio in the options market was as high as 68%, reflecting overheated market sentiment and short-term selling pressure.
- Profitability Authenticity Challenge: Adjusted net profit continues to decline, free cash flow relies on external financing, endogenous hematopoietic capacity is weakened, and fundamental support is questioned.
Metrics to watch
- Next quarter financial report release (expected to be January 2027): It will reveal the commercialization progress of new drugs, cost control effectiveness and profitability sustainability, and is a key window to verify growth expectations.
- Litigation case progress and compensation amount disclosure: Focus on regulatory developments in the EU, China, Japan and other places, as well as the results of class action lawsuits, which directly affect the company's credit and asset value.
- Free cash flow composition analysis: Track the changes in the proportion of non-operating cash flow. If it continues to be higher than 50%, it will strengthen concerns about "unsustainability".
- Institutional capital flows and position changes: Monitor the main capital movements through terminals such as Bloomberg to determine whether there are large-scale withdrawal signals.
- Changes in RSI and MACD indicators: If RSI enters the overbought zone above 70 or there is a price top divergence, combined with shrinking trading volume, it may indicate the risk of a short-term correction.